Tamboli Ajim 4

What Happened
Ajim Tamboli, CFO of First Tracks Biotherapeutics (TRAX), received two awards on 2026-05-12 totaling 18,600 restricted stock units (RSUs): 5,000 RSUs and 13,600 RSUs. Both grants were reported as derivative awards at $0.00 per unit (no cash paid). Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration (see footnote F1).

Key Details

• Transaction date: 2026-05-12; filing date: 2026-05-14 (appears timely).
• Award amounts and price: 5,000 RSUs @ $0.00 and 13,600 RSUs @ $0.00 (total 18,600 RSUs).
• Vesting for the RSUs: 25% of the total RSUs vest annually beginning May 12, 2027 until fully vested, subject to continued service (footnote F2).
• Additional vesting/option notes: footnote F3 describes an option vesting schedule (25% on May 12, 2027, then 1/48 monthly) and footnote F4 states the Reporting Person also holds options to purchase additional shares (including up to 123,700 aggregate shares).
• Shares owned after transaction: not specified in the provided excerpt of the filing.
• Transaction type: Award/Grant (code A) — not a purchase or sale; no immediate market transaction occurred.

Context
This was a grant of RSUs (deferred equity compensation) rather than an open-market purchase or sale. Because RSUs convert to actual shares only after vesting and settlement, there was no immediate change to market float or sale activity. Such grants are common forms of executive compensation and reflect compensation decisions, not direct buying or selling by the insider.